RET (G810S/M918T)
Sign in to save this workspaceRET · Variant type: compound · HGVS: p.G810S;p.M918T
Components
p.G810Sp.M918T
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 61.7% | 38.3% | 84.21 |
| 2 | Gilteritinib | 54.4% | 45.6% | 88.97 |
| 3 | Sunitinib | 45.0% | 55.0% | 91.73 |
| 4 | Canertinib | 32.7% | 67.3% | 96.49 |
| 5 | Vandetanib | 27.7% | 72.3% | 95.74 |
| 6 | Capivasertib | 18.3% | 81.7% | 96.48 |
| 7 | Acalabrutinib | 9.5% | 90.5% | 99.50 |
| 8 | Erlotinib | 7.0% | 93.0% | 99.75 |
| 9 | Remibrutinib | 2.6% | 97.4% | 99.50 |
| 10 | Palbociclib | 2.4% | 97.6% | 98.75 |
| 11 | Inavolisib | 0.1% | 99.9% | 100.00 |
| 12 | Abemaciclib | 0.0% | 100.0% | 91.48 |
| 13 | Cobimetinib | 0.0% | 100.0% | 100.00 |
| 14 | Darovasertib | 0.0% | 100.0% | 96.99 |
| 15 | Quizartinib | 0.0% | 100.0% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 61.7% | — | — |
| Gilteritinib | 54.4% | 100.0% | -45.6% |
| Sunitinib | 45.0% | 97.2% | -52.2% |
| Canertinib | 32.7% | — | — |
| Vandetanib | 27.7% | 98.6% | -70.9% |
| Capivasertib | 18.3% | — | — |
| Acalabrutinib | 9.5% | — | — |
| Erlotinib | 7.0% | — | — |
| Remibrutinib | 2.6% | — | — |
| Palbociclib | 2.4% | — | — |
| Inavolisib | 0.1% | — | — |
| Abemaciclib | 0.0% | — | — |
| Cobimetinib | 0.0% | — | — |
| Darovasertib | 0.0% | — | — |
| Quizartinib | 0.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.1ms